Apotex Pharmachem Pharmaceutical Purity Ingredients Distributor CAS numbers MSDS
reagent STA-NeoPTimal on a STA R Max analyzer for the measurement of prothrombin time
Induction of posterior vitreous detachment (PVD) by non-enzymatic reagents concentrating on vitreous collagen liquefaction in addition to vitreoretinal adhesion
Induction of posterior vitreous detachment (PVD) by pharmacologic vitreolysis has been largely tried by way of using enzymatic reagents. Ocriplasmin has been the one FDA-approved scientific reagent to date. A number of hostile results of ocriplasmin have emerged, nonetheless, and the seek for various PVD-inducing reagents continues.
Since i) collagen varieties an vital structural element of the vitreous, and ii) robust vitreo-retinal adhesions exist between the cortical vitreous and the inner limiting membrane (ILM) of the retina, an efficient PVD-inducing reagent would require each, vitreous liquefaction, and concurrent dehiscence of vitreoretinal adhesion, with out being poisonous to retinal cells. We designed a mixture of two reagents to realize these two goals; a triple helix-destabilizing collagen binding area (CBD), and a fusion of RGD (integrin-binding) tripeptide with CBD (RCBD) to facilitate separation of posterior cortical vitreous from retinal floor.
Based mostly on in vitro, ex-vivo, and in vivo experiments, we present {that a} mixture of CBD and RCBD shows potential for protected pharmacologic vitreolysis. Our findings assume significance in gentle of the truth that artificial RGD-containing peptides have already been used for inhibition of tumor cell invasion. Proteins similar to variants of collagen binding domains might have prolonged therapeutic makes use of sooner or later.
Description: LEC is a CC chemokine that can signal through the CCR8 and CCR1 receptors. It is expressed in the liver, spleen, and thymus. LEC is chemotactic towards monocytes and lymphocytes but not neutrophils. Recombinant human LEC is an 11.2 kDa protein containing 97 amino acid residues, including the four conserved cysteine residues present in CC chemokines.
Description: LEC is a CC chemokine that can signal through the CCR8 and CCR1 receptors. It is expressed in the liver, spleen, and thymus. LEC is chemotactic towards monocytes and lymphocytes but not neutrophils. Recombinant human LEC is an 11.2 kDa protein containing 97 amino acid residues, including the four conserved cysteine residues present in CC chemokines.
Description: CCL16 Human Recombinant produced in E.Coli is a non-glycosylated, Polypeptide chain containing 97 amino acids and having a molecular mass of 11.2 kDa. ;The CCL16 is purified by proprietary chromatographic techniques.
Recombinant Caenorhabditis Elegans lec-7 Protein (aa 1-179)
Description: A Monoclonal antibody against Human HCC-4 / Liver Expressed Chemokine (LEC) - With BSA and Azide. The antibodies are raised in Mouse and are from clone LEC66. This antibody is applicable in E
Monoclonal HCC-4 / Liver Expressed Chemokine (LEC) Antibody - With BSA and Azide, Clone: LEC67
Description: A Monoclonal antibody against Human HCC-4 / Liver Expressed Chemokine (LEC) - With BSA and Azide. The antibodies are raised in Mouse and are from clone LEC67. This antibody is applicable in E
Monoclonal HCC-4 / Liver Expressed Chemokine (LEC) Antibody - Without BSA and Azide, Clone: LEC66
Description: A Monoclonal antibody against Human HCC-4 / Liver Expressed Chemokine (LEC) - Without BSA and Azide. The antibodies are raised in Mouse and are from clone LEC66. This antibody is applicable in E
×
Applicability of ninhydrin as a fluorescent reagent for estimation of teicoplanin in human plasma utilizing salting-out assisted liquid-liquid extraction method
The applicability of ninhydrin, a broadly used derivatizing reagent, for dedication of teicoplanin (TEIC) in its pure kind, pharmaceutical vials, and in human plasma was investigated. The offered spectrofluorimetric methodology was based mostly on a condensation response between ninhydrin and the first amine group current in TEIC (within the presence of phenylacetaldehyde) to supply a extremely fluorescent product detected at 460 nm (λex ,390 nm). Calibration plots have been constructed within the focus vary 60-600 ng mL-1 with a great correlation coefficient of 0.9998 and a low detection restrict of 10.84 ng mL-1 .
The strategy was subjected to a bioanalytical validation research in line with US-FDA suggestions. The proposed methodology was utilized for evaluation of TEIC in industrial vials with excessive restoration outcome 101.88 ± 1.11%. As well as, the methodology was utilized effectively for detection of TEIC in human plasma utilizing salting-out assisted liquid-liquid extraction method (SALLE) with a restoration vary from 96.71 ± 1.08% to 97.71 ± 0.86%. SALLE is an efficient method used for extraction of TEIC from human plasma with out interferences utilizing ammonium sulphate. The proposed methodology is very advisable to watch TEIC in scientific laboratory samples and therapeutic drug monitoring methods.
Analysis of a brand new thromboplastin reagent STA-NeoPTimal on a STA R Max analyzer for the measurement of prothrombin time, worldwide normalized ratio and extrinsic issue ranges
Introduction: We geared toward evaluating the efficiency of a brand new prothrombin time (PT) reagent (STA-NeoPTimal) with two different PT reagents (STA-Neoplastine R and STA-Neoplastine CI Plus) and the reference PT reagent utilized in our laboratory (ReadiPlasTin).
Strategies: Analysis consisted in intra- and interassay precision evaluation, dedication of sensitivity to unfractionated heparin (UFH) or enoxaparin in spiked samples and to direct oral anticoagulants (DOACs) in sufferers (n = 43). Technique comparability of the four PT reagents, issue II, V, VII and X assays was examined on regular (n = 20) and irregular samples: VKA (n = 47), preoperative (n = 23), liver failure (n = 12) and burned sufferers (n = 37).
Outcomes: Analytical efficiency met producers’ standards for all reagents. All PT reagents gave correlation coefficients >0.eight and even >0.9 in lots of conditions. In some VKA samples, variations ≥ 0.5 INR models have been present in samples inside and above therapeutic ranges. For burned sufferers, PT correlations have been good however with some minimal bias (<5.0%) whereas issue assays gave very constant outcomes (R > .eight and primarily >0.9). As anticipated, poor responsiveness of the PT to DOAC concentrations was noticed with all 4 assays.
Conclusion: The STA-NeoPTimal confirmed comparable efficiency to ReadiPlasTin, making it appropriate for VKA management, detection of things II, V, VII, X deficiency and evaluation of liver illness coagulopathy. Nonetheless, for sufferers receiving VKA, some important variations have been noticed. We confirmed the lack of the PT assay to detect residual DOAC concentrations. Lastly, burned sufferers outcomes confirmed that recombinant thromboplastins have been much less delicate to issue deficiencies compared to extraction thromboplastins.
Description: The CD80 antigen (B7, BB1) recognizes a 60 kDa transmembrane glycoprotein, member of the immunoglobulin family. This molecule shares with CD86 the capability to be the ligand for two structurally similar molecules expressed on T lymphocytes, CD28 and CD152 (CTLA-4). CD80 antigen is expressed on in vitro activated B lymphocytes. It is not expressed on the majority of resting B cells from peripheral blood but identifies a subpopulation of B cells that has been previously activated. The antigen is also expressed by HTLV-1 transformed T cells activated monocytes, and constitutively on dendritic cells. CD80 binding provides costimulatory signals for T cell activation.
Description: A polyclonal antibody against CD80. Recognizes CD80 from Human. This antibody is Unconjugated. Tested in the following application: IHC, ELISA;IHC-p:1:50-300, ELISA:1:10000-20000
Description: A polyclonal antibody against CD80. Recognizes CD80 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:1000-1:2000, IHC:1:25-1:100
Description: A polyclonal antibody against CD80. Recognizes CD80 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, IHC;ELISA:1:2000-1:5000, IHC:1:50-1:200
Description: A polyclonal antibody against CD80. Recognizes CD80 from Human. This antibody is Unconjugated. Tested in the following application: ELISA, WB
